Several EZH2 inhibitors including 3-DZNep are currently being tested in pre-clinical models, and other inhibitors, such as GSK126, EPZ-6438, CPI-1205 are under clinical trials as anti-cancer drugs14. The gene discussed is EZH2; the disease is cancer.